Nantahala Capital Management LLC Takes Position in RAPT Therapeutics, Inc. (NASDAQ:RAPT)

Nantahala Capital Management LLC acquired a new stake in shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 1,243,513 shares of the company's stock, valued at approximately $1,965,000. Nantahala Capital Management LLC owned about 3.56% of RAPT Therapeutics at the end of the most recent reporting period.

Several other large investors have also modified their holdings of RAPT. Medicxi Ventures Management Jersey Ltd acquired a new stake in RAPT Therapeutics during the fourth quarter worth about $35,316,000. Foresite Capital Management VI LLC purchased a new position in RAPT Therapeutics in the fourth quarter valued at about $19,750,000. ADAR1 Capital Management LLC lifted its stake in shares of RAPT Therapeutics by 15,557.5% during the fourth quarter. ADAR1 Capital Management LLC now owns 1,174,313 shares of the company's stock worth $1,855,000 after purchasing an additional 1,166,813 shares in the last quarter. Affinity Asset Advisors LLC acquired a new stake in shares of RAPT Therapeutics in the fourth quarter valued at about $1,580,000. Finally, JPMorgan Chase & Co. raised its holdings in shares of RAPT Therapeutics by 1,128.3% during the 4th quarter. JPMorgan Chase & Co. now owns 205,164 shares of the company's stock valued at $324,000 after buying an additional 188,461 shares during the period. 99.09% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a "buy" rating and set a $10.00 price objective on shares of RAPT Therapeutics in a research note on Monday, March 10th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $4.00.

RAPT Therapeutics Stock Performance

Shares of RAPT Therapeutics stock traded up $0.05 during trading hours on Friday, reaching $0.97. The company's stock had a trading volume of 904,905 shares, compared to its average volume of 1,277,851. RAPT Therapeutics, Inc. has a one year low of $0.75 and a one year high of $8.58. The company's 50 day simple moving average is $1.06 and its 200 day simple moving average is $1.29. The stock has a market cap of $127.62 million, a P/E ratio of -0.35 and a beta of -0.29.

RAPT Therapeutics (NASDAQ:RAPT - Get Free Report) last posted its earnings results on Thursday, March 6th. The company reported ($1.14) EPS for the quarter, missing the consensus estimate of ($0.45) by ($0.69). On average, sell-side analysts predict that RAPT Therapeutics, Inc. will post -2.14 earnings per share for the current fiscal year.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.